Target intelligence / Profile preview

Fc-gamma receptor and complement component C1q (FcγR and C1q)

Target
FcγR and C1q
Molecular classification
Receptor, Immunoglobulin receptor, Immune checkpoint, Pattern recognition molecule, Complement protein, Soluble immune mediator
01

Overview

Fc-gamma receptors (FcγRs) and complement component C1q are distinct but functionally interconnected immune molecules. FcγRs are cell surface receptors expressed primarily on immune cells such as macrophages, neutrophils, and natural killer cells; they recognize the Fc region of IgG antibodies and mediate key effector functions including antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis. C1q is a soluble pattern recognition molecule that initiates the classical complement pathway by binding to aggregated immunoglobulins (IgG or IgM) or pathogen surfaces, leading to downstream complement activation, opsonization, and lytic attack on targets. The biological activities of therapeutic antibodies depend heavily on their ability to engage FcγRs and/or C1q, and these functions can be differentially engineered to bias immune effector mechanisms. Binding of C1q and FcγRs can also be mutually exclusive, as decoration with C1q may inhibit FcγR engagement on immune complexes, indicating complementary and regulatory roles in immune homeostasis. Both molecules are involved in autoimmunity, infection, tumor immunity, and are targets for immunomodulation through therapeutic antibodies. Note: The query describes an artificial composite target. Scientifically, "Fc-gamma receptor" and "complement component C1q" are distinct and should be treated as separate canonical entries.

Other names
Fc gamma receptorFcγ receptorCD16 (FcγRIII)CD32 (FcγRII)CD64 (FcγRI)Fc receptor for IgGC1qComplement subcomponent C1q
02

Mechanism of action

Antibody-dependent cellular cytotoxicity (ADCC) via FcγRs: Antibody binding to antigen on target cells, Fc region of antibody binds FcγRs on immune effector cells (e.g., NK cells), leading to cell death. Antibody-dependent cellular phagocytosis (ADCP): FcγRs on phagocytes engage IgG-opsonized particles, resulting in phagocytosis. Complement-dependent cytotoxicity (CDC): C1q binds to Fc of clustered IgG or IgM on cell surfaces, triggers classical complement cascade, and results in cell lysis or opsonization.

03

Biological functions

Immune responsePhagocytosisAntibody-dependent cellular cytotoxicity (ADCC)Signal transductionInitiation of classical complement pathwayClearance of apoptotic cellsImmune complex handlingRegulation of inflammation
04

Disease associations

Autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis)InfectionCancerNeurodegenerative disease (especially for C1q, in relation to synaptic pruning and neuroinflammation)
05

Safety considerations

Excessive activation can lead to systemic inflammation, cytokine release syndromeRisk of autoimmunity (e.g., SLE associated with C1q deficiency)Tissue damage due to complement activationOff-target cytotoxicity due to therapeutic antibodies
06

Interacting drugs

Monoclonal antibodies (e.g. rituximab, trastuzumab, obinutuzumab)

2 more in the full profile.

07

Biomarkers

Surface expression of FcγRs can be used to stratify immune cell subsets (e.g., CD16 on NK cells)C1q levels in serum are used as a marker for complement activation or deficiency (e.g., SLE monitoring)FcγR polymorphisms have been associated with response to some antibody therapies

Beyond the preview

Go deeper on Fc-gamma receptor and complement component C1q (FcγR and C1q).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fc-gamma receptor and complement component C1q (FcγR and C1q).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call